Molecular Neurobiology

, Volume 54, Issue 1, pp 748–754 | Cite as

Pramlintide Antagonizes Beta Amyloid (Aβ)- and Human Amylin-Induced Depression of Hippocampal Long-Term Potentiation

  • R. Kimura
  • D. MacTavish
  • J. Yang
  • D. Westaway
  • Jack H. Jhamandas


Accumulation of amyloid-β peptide (Aβ) is a pathological hallmark of Alzheimer’s disease (AD). We have previously demonstrated that electrophysiological and neurotoxic effects of Aβ and human amylin are expressed via the amylin receptor. Recently, pramlintide, a synthetic analog of amylin, has been reported to improve cognitive function in transgenic AD mouse models. In this study, we examined the effects of pramlintide on Aβ1–42 and human amylin-evoked depression of long-term potentiation (LTP) at Schaeffer collateral-CA1 hippocampal synapses. In mouse hippocampal brain slices, field excitatory postsynaptic potentials (fEPSPs) were recorded from the stratum radiatum layer of the CA1 area in response to electrical stimulation of Schaeffer collateral afferents and LTP induced by 3-theta-burst stimulation (TBS) protocol. Aβ1–42 (50 nM) and human amylin (50 nM), but not Aβ42–1 (50 nM), depressed LTP. Pre-application of pramlintide (250 nM) blocked Aβ- and human amylin-induced reduction of LTP without affecting baseline transmission or LTP. We also examined the effects of pramlintide on LTP in transgenic mice (TgCRND8) that over-express amyloid precursor protein. In contrast to wild-type controls, where robust LTP was observed, 10- to 12-month-old TgCRND8 mice show blunted LTP. In TgCRND8 mice, basal LTP is enhanced by application of pramlintide. Our data indicate that pramlintide acts as a functional amylin receptor antagonist to reverse the effects of Aβ1–42 and human amylin on LTP and also increases LTP in transgenic mice that demonstrate increased ambient brain amyloid levels. Amylin receptor antagonists may thus serve as potentially useful therapeutic agents in treatment of AD.


Alzheimer’s disease Diabetes Hippocampus LTP Amyloid Amylin receptor Synaptic plasticity 



This research was supported by funding from the Canadian Institutes of Health Research (MOP 93601 to JHJ) and the Alberta Prion Research Institute (APRI 201400009 to DW). RK was a recipient of an Alberta Innovates—Health Solutions Visiting Scientist award.

Compliance with Ethical Standards

All experiments were carried out in compliance with the relevant laws and guidelines set by the Canadian Council for Animal Care and with the approval of the Human Research Ethics Board and Animal Care Use Committee (Health Sciences) at the University of Alberta.

Conflict of Interest

The authors declare that they have no competing interests.


  1. 1.
    Skovronsky DM, Lee VM, Trojanowski JQ (2006) Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol 1:151–170CrossRefPubMedGoogle Scholar
  2. 2.
    Querfurth HW, LaFerla FM (2010) Alzheimer’s disease. N Engl J Med 362(4):329–344CrossRefPubMedGoogle Scholar
  3. 3.
    Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148:204–222Google Scholar
  4. 4.
    Selkoe D (1994) Normal and abnormal biology of the β-amyloid precursor protein. Annu Rev Neurosci 17:489–517CrossRefPubMedGoogle Scholar
  5. 5.
    Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–356CrossRefPubMedGoogle Scholar
  6. 6.
    Selkoe DJ (2013) The therapeutics of Alzheimer’s disease: where we stand and where we are heading. Ann Neurol 74:328–336CrossRefPubMedGoogle Scholar
  7. 7.
    Hardy J (2009) The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal. J Neurochem 110:1129–1134CrossRefPubMedGoogle Scholar
  8. 8.
    Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A et al (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 349:704–706CrossRefPubMedGoogle Scholar
  9. 9.
    Dore S, Kar S, Quirion R (1997) IGF-I protects and rescues hippocampal neurones against β-amyloid and human amylin-induced toxicity. Proc Natl Acad Sci U S A 94:4772–4777CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Price DL, Wong PC, Markowska AL, Lee MK, Thinakaren G, Cleveland DW, Sisodia SS, Borchelt DR (2000) The value of transgenic models for the study of neurodegenerative diseases. Ann N Y Acad Sci 920:179–191CrossRefPubMedGoogle Scholar
  11. 11.
    Dahlgren KN, Manelli AM, Stine WB, Baker LK, Krafft GA, LaDu MJ (2002) Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J Biol Chem 277(35):32046–32053CrossRefPubMedGoogle Scholar
  12. 12.
    Jhamandas JH, MacTavish D (2004) Antagonist of the amylin receptor blocks β-amyloid toxicity in rat cholinergic basal forebrain neurons. J Neurosci 24:5579–5584CrossRefPubMedGoogle Scholar
  13. 13.
    Jhamandas JH, Li Z, Westaway D, Yang J, Jassar S, MacTavish D (2011) Actions of β-amyloid protein on human neurons are expressed through the amylin receptor. Am J Pathol 178:140–149CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Fu W, Ruangkittisakul A, MacTavish D, Shi J, Ballanyi K, Jhamandas JH (2012) Amyloid beta (Aβ) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signalling pathways. J Biol Chem 287:8820–18830Google Scholar
  15. 15.
    Götz J, Lim Y-A, Eckert A (2013) Lessons from two prevalent amyloidoses—what amylin and Aβ have in common. Front Aging Neurosci 5(38):1–10Google Scholar
  16. 16.
    Young A (2005) Receptor pharmacology. Adv Pharmacol 52:47–65CrossRefPubMedGoogle Scholar
  17. 17.
    Jhamandas JH, MacTavish D (2012) β-amyloid protein (Aβ) and human amylin regulation of apoptotic genes occurs through the amylin receptor. Apoptosis 17:37–47CrossRefPubMedGoogle Scholar
  18. 18.
    Lutz TA, Tschudy S, Rushing PA, Scharrer E (2000) Attenuation of anorectic effects of cholecystokinin and bombesin by the specific amylin antagonist AC253. Physiol Behav 70(5):533–536CrossRefPubMedGoogle Scholar
  19. 19.
    Cantarella G, Martinez G, Di-Benedetto G, Loreto C, Musumeci G, Prato A, Lempeeur L, Matera M et al (2007) Protective effects of amylin on reserpine-induced gastric damage in the rat. Pharmacol Res 56:27–34CrossRefPubMedGoogle Scholar
  20. 20.
    Kimura R, MacTavish D, Yang J, Westaway D, Jhamandas JH (2012) Beta amyloid-induced depression of hippocampal long-term potentiation is mediated through the amylin receptor. J Neurosci 32:17401–17406CrossRefPubMedGoogle Scholar
  21. 21.
    Adler BL, Yarchoan M, Hwang HM, Louneva N, Blair JA, Palm R, Smith MA, Lee HG et al (2013) Neuroprotective effects of the amylin analogue pramlintide on Alzheimer’s disease pathogenesis and cognition. Neurobiol Aging 35(4):793–801CrossRefPubMedGoogle Scholar
  22. 22.
    Zhu H, Wang X, Wallack M, Li H, Carreras I, Dedeoglu A, Hur JY, Zheng H et al (2015) Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer’s disease. Mol Psychiatry 20:252–262CrossRefPubMedGoogle Scholar
  23. 23.
    Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zuker N et al (2001) Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein. J Biol Chem 276:21562–21570CrossRefPubMedGoogle Scholar
  24. 24.
    Kimura R, Devi L, Ohno M (2010) Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer’s disease transgenic mice. J Neurochem 113:248–261CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kimura R, Ohno M (2009) Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Neurobiol Dis 33:229–235CrossRefPubMedGoogle Scholar
  26. 26.
    Stine WB Jr, Dahlgren KN, Krafft GA, LaDu MJ (2003) In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem 278:11612–11622CrossRefPubMedGoogle Scholar
  27. 27.
    Young AA, Vine W, Gedulin BR, Pittner R, Janes S, Caeta LSN, Percy A, Moore CX et al (1996) Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin. Drug Dev Res 37:231–248CrossRefGoogle Scholar
  28. 28.
    Gingell JJ, Burns ER, Hay DL (2014) Activity of pramlintide, rat and human amylin but not Aβ1–42 at human amylin receptors. Endocrinology 155:21–26CrossRefPubMedGoogle Scholar
  29. 29.
    Wang H, Abedini A, Ruzsicska B, Raleigh DP (2014) Rationally designed, nontoxic, nonamyloidogenic analogues of human islet amyloid polypetide with improved solubility. BiochemistryGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • R. Kimura
    • 1
    • 2
  • D. MacTavish
    • 2
    • 4
  • J. Yang
    • 2
    • 4
    • 5
  • D. Westaway
    • 2
    • 3
    • 4
    • 5
  • Jack H. Jhamandas
    • 2
    • 4
  1. 1.Faculty of EngineeringTokyo University of ScienceSanyo-onodaJapan
  2. 2.Department of Medicine (Neurology)University of AlbertaEdmontonCanada
  3. 3.Department of BiochemistryUniversity of AlbertaEdmontonCanada
  4. 4.Neuroscience and Mental Health InstituteUniversity of AlbertaEdmontonCanada
  5. 5.Centre for Prions and Protein Folding DiseasesUniversity of AlbertaEdmontonCanada

Personalised recommendations